{
    "clinical_study": {
        "@rank": "99265", 
        "arm_group": [
            {
                "arm_group_label": "2B3-201 150mg", 
                "arm_group_type": "Experimental", 
                "description": "2B3-201 150mg, once, IV infusion in 1000ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 1000ml 5% dextrose/ Placebo, once, IV infusion 1000ml 5% dextrose"
            }, 
            {
                "arm_group_label": "2B3-201 300mg", 
                "arm_group_type": "Experimental", 
                "description": "2B3-201 300mg, once, IV infusion in 1500ml 5% dextrose/ Methylprednisolone hemisuccinate 300mg, once, IV infusion in 1500ml 5% dextrose/ Placebo, once, IV infusion 1500ml 5% dextrose"
            }, 
            {
                "arm_group_label": "2B3-201 450mg", 
                "arm_group_type": "Experimental", 
                "description": "2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 2500ml 5% dextrose/ Placebo, once, IV infusion 2500ml 5% dextrose"
            }, 
            {
                "arm_group_label": "450mg 2B3-201", 
                "arm_group_type": "Experimental", 
                "description": "2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose"
            }, 
            {
                "arm_group_label": "300mg 2B3-201", 
                "arm_group_type": "Experimental", 
                "description": "2B3-201 300mg, once, IV infusion in 1500ml 5% dextrose"
            }, 
            {
                "arm_group_label": "2B3-201 450mg male volunteers", 
                "arm_group_type": "Experimental", 
                "description": "2B3-201 450mg, once, IV infusion in 1500ml 5% dextrose"
            }, 
            {
                "arm_group_label": "2B3-201 300mg or 450mg female volunteers", 
                "arm_group_type": "Experimental", 
                "description": "2B3-201 300mg or 450mg, once, IV infusion in 1500 or 2500ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 1500 or 2500ml 5% dextrose"
            }, 
            {
                "arm_group_label": "RRMS patients; 2B3-201 450 mg", 
                "arm_group_type": "Experimental", 
                "description": "2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose"
            }
        ], 
        "brief_summary": {
            "textblock": "In this first in human study the aim is to assess the safety, pharmacokinetics and\n      pharmacodynamics of 2B3-201 in a randomized, first in human, double-blind, placebo- and\n      active comparator- controlled 3-way crossover study in 18 healthy male subjects (part 1).\n      Furthermore, the findings obtained from part 1 will be extended and confirmed in a\n      subsequent parallel open label study in 18 healthy male and 6 MS patients and an open label\n      study with methylprednisolone as comparator in 6 female volunteers (part 2)."
        }, 
        "brief_title": "Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Healthy Volunteers", 
            "Multiple Sclerosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Healthy subjects\n\n          -  Healthy male or female subjects, 18 to 45 years of age, inclusive. Healthy status is\n             defined by absence of evidence of any active or chronic disease following a detailed\n             medical and surgical history, a complete physical examination including vital signs,\n             12-lead ECG, hematology, blood chemistry, and urinalysis.\n\n          -  Body mass index (BMI) between 18 and 30 kg/m2, inclusive, and with a minimum weight\n             of 50 kg.\n\n          -  Able to participate and willing to give written informed consent and to comply with\n             the study restrictions.\n\n        Relapsing remitting MS patients\n\n          -  Age: 18 to 65 years, both men and women.\n\n          -  RRMS according to the 2010 McDonald criteria.\n\n          -  An estimated Expanded Disability Status Scale (EDSS) score prior to acute\n             exacerbation: 0 to 5.0.\n\n          -  A moderate (increase 1-2.5 points on EDSS score) or severe (increase \u22653 points on\n             EDSS score) clinical acute exacerbation without improvement at the time of inclusion;\n\n          -  Recent clinical exacerbation onset (<10 days) without fever;\n\n          -  One month of clinical stability prior to the acute exacerbation.\n\n          -  Able to participate and willing to comply with the study restrictions. Understands\n             and signs the written informed consent prior to any of the testing under this\n             protocol, including screening tests and evaluations that are not considered part of\n             the subject's routine care.\n\n        Exclusion Criteria:\n\n        Healthy volunteers:\n\n          -  Any subject who is pregnant or breastfeeding. A urine pregnancy test should be\n             performed in female subjects of childbearing potential (defined as < 2 years after\n             last menstruation and not surgically sterile) prior to the start of the study\n             treatment.\n\n          -  For female subjects of childbearing potential (defined as < 2 years after last\n             menstruation and not surgically sterile) and male subjects who are not surgically\n             sterile or with female partners of childbearing potential: absence of effective,\n             non-hormonal means of contraception (intrauterine contraceptive device, barrier\n             method of contraception in conjunction with spermicidal gel) will be a\n             contraindication.\n\n          -  Not willing to use double-barrier contraception, for the duration of the study and\n             for 3 months after the last dose.\n\n          -  Positive test for drugs of abuse at screening or pre-dose.\n\n          -  History of alcohol consumption exceeding 2 standard drinks per day on average (1\n             standard drink = 10 grams of alcohol) within 3 months of screening.  Alcohol\n             consumption will be prohibited during study confinement and at least 48 hours before\n             screening, before dosing, and before each scheduled visit.\n\n          -  History or symptoms of any significant disease including (but not limited to),\n             neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal,\n             hepatic, or renal disorder.\n\n          -  Positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human\n             immunodeficiency virus antibody (HIV Ab) at screening.\n\n          -  Systolic blood pressure (SBP) greater than 140 mm Hg or less than 90 mm Hg, and\n             diastolic blood pressure (DBP) greater than 90 mm Hg or less than 50 mm Hg.\n\n          -  Use of any medications (prescription or over-the-counter [OTC]), vitamin, mineral,\n             herbal, and dietary supplements within 21 days of study drug administration.\n             Exceptions are paracetamol (up to 4 g/day).\n\n          -  Use of CYP3A4-inhibiting drugs, including quinine containing drinks (bitter lemon and\n             tonic water) is prohibited within 21 days of study drug administration\n\n          -  Subject has used grapefruit, grapefruit juice, grapefruit-containing products,\n             Seville oranges, or pomelo-containing products, within 14 days prior to day -1.\n\n          -  Clinically significant abnormalities, as judged by the investigator, in laboratory\n             test results (including hepatic and renal panels, complete blood count, chemistry\n             panel and urinalysis). In the case of uncertain or questionable results, tests\n             performed during screening may be repeated before randomization to confirm\n             eligibility or judged to be clinically irrelevant for healthy subjects.\n\n          -  Participation in an investigational drug or device study within 3 months prior to\n             screening.\n\n          -  Donation of blood over 500 mL within three months prior to screening.\n\n          -  Concomitant disease or condition that could interfere with, or for which the\n             treatment of might interfere with, the conduct of the study, or that would, in the\n             opinion of the Investigator, pose an unacceptable risk to the subject in this study.\n\n          -  Smoker of more than 10 cigarettes per day prior to screening or who use tobacco\n             products equivalent to more than 10 cigarettes per day.\n\n          -  Clinically significant abnormal ECG, as judged by the Investigator.\n\n          -  Current infection or inflammation study within 1 month prior to screening\n\n          -  Recent vaccinations study within 3 months prior to screening.\n\n          -  Positive Mantoux test of 5 mm or more.\n\n          -  Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any\n             drug, or multiple drug allergies (non-active hay fever is acceptable).\n\n          -  Unwillingness or inability to comply with the study protocol for any other reason.\n\n        MS patients:\n\n          -  Previous acute exacerbations, and/or corticosteroid treatment or ACTH < 1 month\n             before present exacerbation, Primary Progressive Multiple Sclerosis (PPMS) or\n             Secondary progressive MS without superimposed acute exacerbations.\n\n          -  Symptoms of the acute exacerbation include a solitary optical neuritis. Unable to\n             complete the EDSS scoring (while inability to complete one of the other scores would\n             be acceptable).\n\n          -  Peripheral or cranial neuropathy as the sole problem of the acute exacerbation\n             episode.\n\n          -  Hypersensitivity to methylprednisolone.\n\n          -  Prior use of immunosuppressive treatments / disease-modifying drugs (DMDs) other than\n             interferon-beta, glatiramer acetate, fingolimod or teriflunomide within 12 months of\n             the index episode. Shorter periods may be allowed at the discretion of the PI and\n             after approval from the sponsor. Subjects may continue their current therapy with\n             interferons, glatiramer acetate, fingolimod, or teriflunomide throughout the course\n             of the study.\n\n          -  Non-steroidal anti-inflammatory agents, including salicylic acid, should be avoided\n             during the administration of the steroid therapy. If absolutely necessary they are\n             permitted for subjects to treat interferon side effects, when the patient is not\n             responding to acetaminophen/paracetamol.\n\n          -  Current or recent (within 30 days of first study treatment) treatment with any other\n             investigational drug or participation in any other investigational study\n\n          -  Evidence of psychiatric illness\n\n          -  History of any significant cardiac, gastrointestinal, hepatic, pulmonary, renal or\n             active immunosuppressive disease.\n\n          -  Immune deficiency or any other medical conditions that would preclude corticosteroid\n             therapy.\n\n          -  Any patient who is pregnant or breastfeeding. A urine pregnancy test should be\n             performed in female subjects of childbearing potential (defined as < 2 years after\n             last menstruation and not surgically sterile) prior to the start of the study\n             treatment.\n\n          -  For female subjects of childbearing potential (defined as < 2 years after last\n             menstruation and not surgically sterile) and male subjects who are not surgically\n             sterile or with female partners of childbearing potential: absence of effective,\n             non-hormonal means of contraception (intrauterine contraceptive device, barrier\n             method of contraception in conjunction with spermicidal gel) will be a\n             contraindication.\n\n          -  Physical examination results or laboratory findings that may interfere with the\n             planned treatment, affect patient compliance or place the patient at a high risk of\n             treatment-related complications.\n\n          -  Known hypersensitivity to any of the cyclodextrin or any excipients in 2B3-201 (e.g.\n             PEG, Cholesterol, HSPC or GSH)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02048358", 
            "org_study_id": "2B3-201-CR-001", 
            "secondary_id": "2013-004077-28"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "2B3-201 150mg", 
                    "2B3-201 300mg", 
                    "2B3-201 450mg", 
                    "450mg 2B3-201", 
                    "300mg 2B3-201", 
                    "2B3-201 450mg male volunteers", 
                    "2B3-201 300mg or 450mg female volunteers", 
                    "RRMS patients; 2B3-201 450 mg"
                ], 
                "intervention_name": "2B3-201", 
                "intervention_type": "Drug", 
                "other_name": "2B3-201: glutathione PEGylated-liposomal methylprednisolone"
            }, 
            {
                "arm_group_label": [
                    "2B3-201 150mg", 
                    "2B3-201 300mg", 
                    "2B3-201 450mg"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "5% Dextrose"
            }, 
            {
                "arm_group_label": [
                    "2B3-201 150mg", 
                    "2B3-201 300mg", 
                    "2B3-201 450mg", 
                    "2B3-201 300mg or 450mg female volunteers"
                ], 
                "intervention_name": "Methylprednisolone hemisuccinate", 
                "intervention_type": "Drug", 
                "other_name": "Solu-Medrol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Healthy volunteers", 
            "first in human", 
            "2B3-201", 
            "methylprednisolone", 
            "CNS-targeting", 
            "liposomal", 
            "crossover", 
            "placebo controlled", 
            "active controlled", 
            "multiple sclerosis", 
            "multiple sclerosis relapse"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": {
            "contact": {
                "email": "kkanhai@chdr.nl", 
                "last_name": "Kawita Kanhai, MD", 
                "phone": "+31(0)715246468"
            }, 
            "facility": {
                "address": {
                    "city": "Leiden", 
                    "country": "Netherlands", 
                    "zip": "2333 CH"
                }, 
                "name": "Centre for Human Drug Research (CHDR)"
            }, 
            "investigator": {
                "last_name": "Geert-Jan Groeneveld, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "8", 
        "official_title": "Randomized, Double-blind, Placebo- and Active Comparator- Controlled Crossover Study in Healthy Male Subjects and an Open Label Study in Healthy Subjects and MS Patients to Assess the Safety, Pharmacokinetics and Pharmacodynamics of 2B3-201", 
        "other_outcome": [
            {
                "measure": "Optimization of the infusion schedule for 2B3-201 with or without the addition of an anti-histaminic drug to minimize the likelihood of non-allergic infusion reactions.", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "Changes in neurological examination, Expanded Disability Systems Score (EDSS) and Multiple Sclerosis functional composite (MSFC) after a single dose of 2B3-201 in patients with RRMS having an acute disease exacerbation, as a measure of clinical efficacy", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "overall_contact": {
            "email": "IoannaStavrakaki@tobbb.com", 
            "last_name": "Ioanna Stavrakaki, PharmD,PDEng", 
            "phone": "+31(0)713322255"
        }, 
        "overall_official": {
            "affiliation": "Center for Human Drug Research", 
            "last_name": "Geert-Jan Groeneveld, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Safety and tolerability of 2B3-201, in comparison to free methylprednisolone hemisuccinate and placebo and the safety and tolerability of 2B3-201amongst the different study populations: healthy male and female subjects and MS patients, additionally the safety and tolerability of 2B3-201 with hydroxypropyl \u03b2-cyclodextrin added to the infusion bag will be assessed in healthy male subjects", 
                "measure": "Number of subjects with adverse events as a measure of safety and tolerability of 2B3-201", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks"
            }, 
            {
                "description": "Pharmacokinetics of 2B3-201, in comparison to free methylprednisolone hemisuccinate and placebo and the pharmacokinetics of 2B3-201amongst the different study populations: healthy male and female subjects and MS patients. Additionally the pharmacokinetics of 2B3-201 with hydroxypropyl \u03b2-cyclodextrin added to the infusion bag will be assessed in healthy male subjects", 
                "measure": "Pharmacokinetics in plasma of intravenously administered 2B3-201 in terms of Cmax, Volume of distribution, half-life (T1/2), area under the plasma concentration-time curve (AUC), Clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }
        ], 
        "reference": {
            "PMID": "22732475", 
            "citation": "Gaillard PJ, Appeldoorn CC, Rip J, Dorland R, van der Pol SM, Kooij G, de Vries HE, Reijerkerk A. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J Control Release. 2012 Dec 28;164(3):364-9. doi: 10.1016/j.jconrel.2012.06.022. Epub 2012 Jun 23."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02048358"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Neurocart test battery (Pharmaco-EEG, Maze learning, Visual verbal Learning test, Stroop test, Adaptive tracking, VAS Bond & Lader and VAS Bowdle, Eye movements, LSEQ sleep questionnaire) as a measure of pharmacodynamic effects of 2B3-201 on CNS functioning in comparison to free methylprednisolone hemisuccinate and placebo;", 
                "measure": "Measure changes in central nervous system (CNS) functioning after intravenous administration of 2B3-201 by using the Neurocart test battery", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "Changes in levels of Hypothalamic-pituitary-adrenal (HPA) axis hormones as a measure of pharmacodynamic effects of 2B3-201 in comparison to free methylprednisolone hemisuccinate and placebo;", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "Changes in levels of fasting blood glucose as a measure of pharmacodynamic effects of 2B3-201 in comparison to free methylprednisolone hemisuccinate and placebo;", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "Changes in levels of osteocalcin concentrations as a measure of pharmacodynamic effects of 2B3-201 in comparison to free methylprednisolone hemisuccinate and placebo;", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "Changes in levels of lymphocyte count as a measure of pharmacodynamic effects of 2B3-201 in comparison to free methylprednisolone hemisuccinate and placebo;", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "Changes in levels of complement factors during infusion as a measure of pharmacodynamic effects of 2B3-201 in comparison to free methylprednisolone hemisuccinate and placebo;", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks"
            }
        ], 
        "source": "to-BBB technologies B.V.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "to-BBB technologies B.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety Study", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}